Innovations Leading the Biotech Landscape

USD 250.00

* Required Fields

USD 250.00

PAY BY INVOICE

Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across biopharmaceuticals. High-throughput microbial analysis, epigenetic therapies, and targeted drug discovery are profiled through recent innovations. The corresponding clinical trials scenario for acromegaly is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; seq

Table of Contents

Innovations Leading the Biotech LandscapeRecent Biotech and Biopharma AdvancesHigh-throughput Microbial AnalysisEpigenetic Therapy for Autism Spectrum Disorder (ASD)Targeted Therapy for Endocrine Diseases and Endocrine CancerTargeted Formulation for Dermatological IndicationsClinical Trial Analysis and Industry InteractionsClinical Trial Analysis for AcromegalyKey Contacts




Keyword1

Keyword2

Keyword3

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.